StimGuard win approval from the FDA for an investigational device exemption trial of its wireless device to treat overactive bladder syndrome.
StimGuard said it won an investigational device exemption from the FDA for a clinical trial of its micro-size implantable device to treat overactive bladder syndrome. StimGuard said its system uses a small injectable microchip and an external transmitter and requires no invasive surgery to implant. The trial is slated to begin in summer 2015.
News Well, Clinical Trials, Investigational Device Exemption (IDE), Neuromodulation/Neurostimulation, Urology
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1G0i9UC
Cap comentari:
Publica un comentari a l'entrada